GLP-1 receptor
6 drugs Metabolic
3
approved indications
6
Approved Drugs
1
Companies
5
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (1 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (5 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Eli Lilly 6 drugs
By Therapeutic Area
Metabolic 5 drugs
Other 1 drugs
Drugs by Company PRO
By Therapeutic Area
Metabolic 5 drugs
ZEPBOUND, MOUNJARO KWIKPEN, MOUNJARO (AUTOINJECTOR), ZEPBOUND KWIKPEN +1 more
Other 1 drugs
MOUNJARO
Indications Treated
Type 2 diabetes mellitus (adults)Type 2 diabetes mellitus (pediatric patients 10 years of age and older)ObesityObstructive Sleep ApneaOverweight
All Drugs Targeting GLP-1 receptor
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| ZEPBOUND | Eli Lilly | 2023 | 3 | Metabolic |
| MOUNJARO | Eli Lilly | 2022 | 2 | |
| MOUNJARO KWIKPEN | Eli Lilly | 2022 | 2 | Metabolic |
| MOUNJARO (AUTOINJECTOR) | Eli Lilly | 2022 | 2 | Metabolic |
| ZEPBOUND KWIKPEN | Eli Lilly | 2023 | 2 | Metabolic |
| ZEPBOUND (AUTOINJECTOR) | Eli Lilly | 2023 | 2 | Metabolic |